Mucosal vaccines: novel advances in technology and delivery

被引:19
作者
Yuki, Yoshikazu [1 ]
Kiyono, Hiroshi [1 ]
机构
[1] Univ Tokyo, Div Mucosal Immunol, Dept Microbiol & Immunol, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan
基金
比尔及梅琳达.盖茨基金会;
关键词
MucoRice (TM); nasal vaccine; oral vaccine; transcutaneous vaccine; ENTEROTOXIGENIC ESCHERICHIA-COLI; ORAL CHOLERA VACCINES; RESPIRATORY SYNCYTIAL VIRUS; RESEARCH-AND-DEVELOPMENT; HEAT-LABILE TOXIN; DENDRITIC CELLS; IMMUNE-RESPONSES; INFLUENZA-VIRUS; T-CELLS; PROTECTIVE IMMUNITY;
D O I
10.1586/ERV.09.61
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mucosal vaccines are considered the most suitable type of vaccines to combat emerging and re-emerging infectious diseases because of their ability to induce both mucosal and systemic immunity. Considerable advances have been made toward the development of mucosal vaccines against influenza virus and rotavirus. Many additional mucosal vaccines are in development, including vaccines against cholera, typhoid, traveler's diarrhea and respiratory infections. In addition to oral and nasal vaccines, transcutaneous (or skin patch) and sublingual immunizations are now part of a new generation of mucosal vaccines. Furthermore, a rice-based oral vaccine (MucoRice (TM)) has been receiving global attention as a new form of cold chain-free vaccine, because it is stable at room temperature for a prolonged period. This review describes recent developments in mucosal vaccines with promising preclinical and clinical results.
引用
收藏
页码:1083 / 1097
页数:15
相关论文
共 119 条
[1]   Safety of sublingual immunotherapy with a monomeric allergoid in very young children [J].
Agostinis, F ;
Tellarini, L ;
Canonica, GW ;
Falagiani, P ;
Passalacqua, G .
ALLERGY, 2005, 60 (01) :133-133
[2]   Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis [J].
Ali, M ;
Emch, M ;
von Seidlein, L ;
Yunus, M ;
Sack, DA ;
Rao, M ;
Holmgren, J ;
Clemens, JD .
LANCET, 2005, 366 (9479) :44-49
[3]   The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis [J].
Andersen, Claire Swetman ;
Dietrich, Jes ;
Agger, Else Marie ;
Lycke, Nils Y. ;
Lovgren, Karin ;
Andersen, Peter .
INFECTION AND IMMUNITY, 2007, 75 (01) :408-416
[4]   Mucosal vaccination against bacterial respiratory infections [J].
Baumann, Ulrich .
EXPERT REVIEW OF VACCINES, 2008, 7 (08) :1257-1276
[5]   Current status of live attenuated influenza virus vaccine in the US [J].
Belshe, RB .
VIRUS RESEARCH, 2004, 103 (1-2) :177-185
[6]   Live attenuated versus inactivated influenza vaccine in infants and young children [J].
Belshe, Robert B. ;
Edwards, Kathryn M. ;
Vesikari, Timo ;
Black, Steven V. ;
Walker, Robert E. ;
Hultquist, Micki ;
Kemble, George ;
Connor, Edward M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07) :685-696
[7]   Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells [J].
Belyakov, IM ;
Hammond, SA ;
Ahlers, JD ;
Glenn, GM ;
Berzofsky, JA .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (07) :998-1007
[8]   Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial [J].
Bernstein, DI ;
Sack, DA ;
Rothstein, E ;
Reisinger, K ;
Smith, VE ;
O'Sullivan, D ;
Spriggs, DR ;
Ward, RL .
LANCET, 1999, 354 (9175) :287-290
[9]   Intussusception and rotavirus vaccines [J].
Bines, Julie .
VACCINE, 2006, 24 (18) :3772-3776
[10]  
Brandt L, 1996, J IMMUNOL, V157, P3527